Isotretinoin REMS Modifications Show How Advisory Panel Can Push FDA To Change Its Mind
Executive Summary
US FDA makes five changes to ease burden of risk management program for acne drug – going further than the agency initially seemed comfortable with in March, though not always in line with what the generic sponsors were seeking.